Kristine Peterson

CIK: 0001508596

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

MLYS

Mineralys Therapeutics, Inc.

Director

AVBP

ArriVent BioPharma, Inc.

Director

IMCR

Immunocore Holdings plc

Director

ENTA

ENANTA PHARMACEUTICALS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

MLYS
Mineralys Therapeutics, Inc.
Oct 19, 2026
Award(A)
Direct
12.4K shares-
AVBP
ArriVent BioPharma, Inc.
Jun 18, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
13.6K shares-
IMCR
Immunocore Holdings plc
May 27, 2026
Award(A)
Share Option (Right to Buy)
Direct
27.5K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Mar 11, 2026
Award(A)
Stock Option (right to buy)
Direct
20K shares-
AVBP
ArriVent BioPharma, Inc.
Jun 18, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
15.5K shares-
IMCR
Immunocore Holdings plc
May 15, 2025
Award(A)
Share Option (Right to Buy)
Direct
26.2K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Mar 13, 2025
Award(A)
Stock Option (right to buy)
Direct
15.7K shares-

		Type	Shares	Price		Ownership
Oct 19, 2026	MLYS Mineralys Therapeutics, Inc.	Award(A)	12,400	-	$0	Direct
Jun 18, 2026	AVBP ArriVent BioPharma, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	13,562	-	-	Direct
May 27, 2026	IMCR Immunocore Holdings plc	Award(A) Share Option (Right to Buy)	27,492	-	-	Direct
Mar 11, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	20,000	-	-	Direct
Jun 18, 2025	AVBP ArriVent BioPharma, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	15,502	-	-	Direct
May 15, 2025	IMCR Immunocore Holdings plc	Award(A) Share Option (Right to Buy)	26,198	-	-	Direct
Mar 13, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	15,700	-	-	Direct

1-7 of 7 transactions

About Peterson Kristine

Peterson Kristine (SEC CIK 0001508596) files insider reports with the SEC as Director of Mineralys Therapeutics, Inc. (MLYS), Director of ArriVent BioPharma, Inc. (AVBP) and Director of Immunocore Holdings plc (IMCR). Signal8 also holds filings tied to 1 other company.

Signal8 holds 8 ownership filings by Peterson Kristine (1 Form 3, 7 Form 4), filed between Mar 14, 2025 and Oct 20, 2026. Those filings report 7 transactions, from Mar 13, 2025 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Peterson Kristine's filings is in RADNOR, PA.

Recent filings by Peterson Kristine

Oct 19, 2026: Grant or award of MLYS shares (Form 4, code A).
Jun 18, 2026: Grant or award of AVBP derivative securities (Form 4, code A).
May 27, 2026: Grant or award of IMCR derivative securities (Form 4, code A).
Mar 11, 2026: Grant or award of ENTA derivative securities (Form 4, code A).
Jun 18, 2025: Grant or award of AVBP derivative securities (Form 4, code A).

Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)

COATS LONNEL, Director
Congleton Jon, Chief Executive Officer
Slingsby Brian Taylor, Director
Warren Eric, Chief Commercial Officer
Karydas Daphne, Director
Ferguson James J. III, Chief Medical Officer

How to read Form 4 transaction codes